FATE — Fate Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $147.65m
- -$56.00m
- $6.65m
Annual income statement for Fate Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 55.8 | 96.3 | 63.5 | 13.6 | 6.65 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 273 | 405 | 254 | 224 | 154 |
| Operating Profit | -217 | -308 | -191 | -210 | -148 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -212 | -282 | -161 | -186 | -136 |
| Net Income After Taxes | -212 | -282 | -161 | -186 | -136 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -212 | -282 | -161 | -186 | -136 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -212 | -282 | -161 | -186 | -136 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.24 | -2.91 | -1.64 | -1.51 | -1.15 |